August 15, 2022
  • Oliver Wyman released findings on the number of private equity deals in health care during the first six months of 2022. According to the analysis, the number of deals declined significantly compared to the same period in prior years. Pharmaceuticals and health tech each accounted for about 36 percent of total capital investments. However, pharmaceutical deals fell 33 percent, dropping from almost 1,200 deals in the first half of 2021 to approximately 800 deals in 2022. The analysis notes that the drop was a significant driver in the more than 20 percent decline in total deal volume through the first half of 2022. However, the analysts caution that the first half of 2022 could outperform the first half of 2021 because most capital in 2021 was invested in the second half of the year. (Analysis¬†here)